title: Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban.
abstract: Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation. Because of its efficacy and once-a-day dosing, it is commonly preferred in patients with nonvalvular atrial fibrillation and intolerance to warfarin in clinical practice. However, it can result in some adverse effects such as bleeding, rashes and liver injury. Here, we described a very rare adverse reaction of rivaroxaban, jaundice due to intrahepatic cholestasis, appeared in a 71-year-old male patient after taking rivaroxaban.
authors.affiliation: aDepartment of Cardiology, Ankara Ataturk Education and Research Hospital bDepartment of Cardiology, Yildirim Beyazit University cDepartment of Gastroenterology, Ankara Ataturk Education and Research Hospital, Ankara, Turkey.
authors.forename: Abdullah N
authors.initials: AN
authors.lastname: Aslan
authors.forename: Cenk
authors.initials: C
authors.lastname: Sari
authors.forename: Serdal
authors.initials: S
authors.lastname: Baştuğ
authors.forename: Sevil Ö
authors.initials: SÖ
authors.lastname: Sari
authors.forename: Murat
authors.initials: M
authors.lastname: Akçay
authors.forename: Tahir
authors.initials: T
authors.lastname: Durmaz
authors.forename: Engin
authors.initials: E
authors.lastname: Bozkurt
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D002780:Cholestasis, Intrahepatic / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D007565:Jaundice / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D020913:Perindopril / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D000069552:Rivaroxaban / Q000009:adverse effects*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D000069552:Rivaroxaban; D020913:Perindopril